https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-purpose-health-ai-leadership BiopharmaWatch en 2026-07-27T11:10:00.000Z Healthcare Triangle Creates "Purpose Health" to Monetize AI Demand and Accelerate Shareholder Returns https://www.biopharmawatch.com/news/DTIL/precision-biosciences-leadership-changes-clinical-milestones BiopharmaWatch en 2026-07-27T11:01:00.000Z Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones https://www.biopharmawatch.com/news/GKOS/glaukos-preserflo-microshunt-enrollment-completion BiopharmaWatch en 2026-07-27T11:00:00.000Z Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt https://www.biopharmawatch.com/news/VYNE/yarrow-bioscience-merger-vyne-therapeutics-phase-2-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease https://www.biopharmawatch.com/news/GOSS/gossamer-bio-fda-update-seralutinib-reacquisition BiopharmaWatch en 2026-07-27T11:00:00.000Z Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update https://www.biopharmawatch.com/news/AZN/astrazeneca-h1-q2-2026-results BiopharmaWatch en 2026-07-27T11:00:00.000Z AstraZeneca results: H1 and Q2 2026 https://www.biopharmawatch.com/news/BHVN/biohaven-yale-avilar-trade-secret-verdict BiopharmaWatch en 2026-07-27T11:00:00.000Z Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-positive-results-phase-2-zephyr-trial BiopharmaWatch en 2026-07-27T11:00:00.000Z MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-australian-regulatory-clearance-cmp-002 BiopharmaWatch en 2026-07-27T11:00:00.000Z CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder https://www.biopharmawatch.com/news/NMRA/neumora-nmra-215-toxicology-results-clinical-advancement-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-advancement-vxa-222-program BiopharmaWatch en 2026-07-27T11:00:00.000Z VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb https://www.biopharmawatch.com/news/PMI/picard-medical-nyse-american-compliance-plan BiopharmaWatch en 2026-07-27T11:00:00.000Z Picard Medical Receives NYSE American Acceptance of Compliance Plan https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/HROW/harrow-report-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-27T11:00:00.000Z Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-27T11:00:00.000Z OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 https://www.biopharmawatch.com/news/TDOC/teladoc-health-canada-accreditation-award BiopharmaWatch en 2026-07-27T10:45:00.000Z Teladoc Health Canada Achieves Accreditation Canada Primer Award, Advancing Quality Standards for Virtual and Hybrid Care in Canada https://www.biopharmawatch.com/news/KURA/kura-oncology-darlifarnib-cabozantinib-ccrcc-results BiopharmaWatch en 2026-07-27T10:32:00.000Z Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 https://www.biopharmawatch.com/news/ENSG/ensign-group-q2-2026-results BiopharmaWatch en 2026-07-27T10:04:00.000Z The Ensign Group Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-ide892-phase-1-2-expansion BiopharmaWatch en 2026-07-27T10:00:00.000Z IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers https://www.biopharmawatch.com/news/PFSA/profusa-management-changes-acquisition-term-sheet BiopharmaWatch en 2026-07-27T10:00:00.000Z Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company https://www.biopharmawatch.com/news/LEGN/legend-biotech-ceo-transition BiopharmaWatch en 2026-07-27T10:00:00.000Z Legend Biotech Announces CEO Transition https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-07-27 BiopharmaWatch en 2026-07-27T07:15:36.214Z Biotech Catalysts to Watch: Key Developments for 2026 and Beyond https://www.biopharmawatch.com/news/ARGX/argenx-acquires-forte-biosciences-immunology-pipeline BiopharmaWatch en 2026-07-27T05:07:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline https://www.biopharmawatch.com/news/FBRX/argenx-acquires-forte-biosciences-anti-cd122-antibody BiopharmaWatch en 2026-07-27T05:00:00.000Z argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ceo-dajun-yang-power-list-2026 BiopharmaWatch en 2026-07-26T23:30:00.000Z Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 https://www.biopharmawatch.com/news/RXST/rxsight-inducement-grants-nasdaq-listing-rules BiopharmaWatch en 2026-07-26T20:00:00.000Z RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-chmp-recommendation-ubeslo-evlarco BiopharmaWatch en 2026-07-26T17:59:00.000Z NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib) https://www.biopharmawatch.com/news/OLMA/5gringos-registration-steps-norway BiopharmaWatch en 2026-07-26T16:13:06.000Z 5Gringos Registration Steps For Players In Norway https://www.biopharmawatch.com/news/OLMA/amazon-slots-registration-steps-belgian-players BiopharmaWatch en 2026-07-26T16:09:31.000Z Amazon Slots Registration Steps For Belgian Players https://www.biopharmawatch.com/news/OLMA/resolving-cashpot-login-issues-dutch-players BiopharmaWatch en 2026-07-26T15:38:54.000Z Resolving Cashpot Login Issues For Dutch Players https://www.biopharmawatch.com/news/OLMA/spinshouse-login-troubleshooting-netherlands-players BiopharmaWatch en 2026-07-26T15:32:46.000Z Spinshouse Login Troubleshooting For Netherlands Players https://www.biopharmawatch.com/news/OLMA/slots-eater-account-login-issues-guide BiopharmaWatch en 2026-07-26T14:24:15.000Z How To Fix SlotsEater Account Login And Access Issues https://www.biopharmawatch.com/news/OLMA/caxino-deposits-withdrawals-netherlands-payment-methods-fees BiopharmaWatch en 2026-07-26T14:00:02.000Z Caxino Deposits And Withdrawals In The Netherlands: Supported Payment Methods And Fees https://www.biopharmawatch.com/news/OLMA/slotexpress-welcome-bonus-wagering-requirements BiopharmaWatch en 2026-07-25T15:47:33.000Z SlotExpress Welcome Bonus Wagering Requirements Explained https://www.biopharmawatch.com/news/OLMA/pixelbet-welcome-bonus-sweden-conditions BiopharmaWatch en 2026-07-25T15:30:23.000Z Pixelbet Welcome Bonus In Sweden And Its Conditions https://www.biopharmawatch.com/news/OLMA/gamdom-login-verification-issues-uk BiopharmaWatch en 2026-07-25T14:17:25.000Z Resolving Gamdom Login And Verification Issues In The UK https://www.biopharmawatch.com/news/OLMA/gamdom-login-verification-issues-uk BiopharmaWatch en 2026-07-25T14:17:25.000Z Resolving Gamdom Login And Verification Issues In The UK https://www.biopharmawatch.com/news/OLMA/delicious-slots-login-problems-uk-fixes-solutions BiopharmaWatch en 2026-07-25T14:14:09.000Z Delicious Slots Login Problems In The United Kingdom: Fixes And Solutions